Goldline Pharmaceutical — 360° view

Goldline Pharmaceutical, a company in the Pharmaceuticals industry, reported revenue of ₹15 crore and net profit of ₹2.05 crore for the September 2026 quarter.

Goldline Pharmaceutical (BSE: GLPL) closed at ₹29.00 on 20 Nov 2026. Its market capitalisation is ₹28 crore and it trades at 6.8 times earnings.

Share price
₹29.00 (20 Nov 2026)
Market cap
₹28 Cr (20 Nov 2026)
P/E
6.76 (20 Nov 2026)
Revenue
₹15 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
30.6% (FY26)
ROE
39.4% (FY26)
Book value
₹27.0 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹60.00 / ₹28.13 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: GLPL

Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.